Patents
The patent covering Cytovac’s platform technology, ALECSAT, has previously been granted in all important regions and today exists as issued patents in the USA and in GB. An international patent application (WO 2020/208054) covering the most recently implemented and improved version of the ALECSAT technology was filed in April 2020, claiming priority from an April 2019 patent filing.
In early 2021 Cytovac filed a priority founding patent application relating to treatment of COVID-19 patients with a modified version of its ALECSAT technology platform.
